Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney in adults

Document first published:
Page updated:
Topic:
Publication type:
,

This clinical commissioning policy statement outlines the commissioning arrangements for rituximab for refractory glomerulosclerosis in the native kidney for adults.

Document

Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney (adults) policy statement

Rituximab for the treatment of refractory focal segmental glomerulosclerosis in the native kidney (adults) policy statement

  • PDF
  • 75 KB
  • 4 pages

Document

Stakeholder Engagement Report

Stakeholder Engagement Report

  • PDF
  • 45 KB
  • 3 pages

Document

CPAG Summary Report

CPAG Summary Report

  • PDF
  • 76 KB
  • 4 pages

Document

Evidence Report

Evidence Report

  • PDF
  • 17 KB
  • 2 pages